MTOR and kaposiform hemangioendothelioma: Since the first reports on the successful use of mammalian target of rapamycin (mTOR) inhibition for the treatment of kaposiform hemangioendothelioma (KHE), sirolimus rapidly evolved from a compassionate use agent to an established therapeutic option for this entity (1, 2).